{"id":390296,"date":"2019-12-27T00:00:00","date_gmt":"2019-12-27T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0015-2019-biopharma-gastroesophageal-cancer-disease-landscape-forecast-g7-2019\/"},"modified":"2026-04-29T11:38:08","modified_gmt":"2026-04-29T11:38:08","slug":"dlsfon0015-2019-biopharma-gastroesophageal-cancer-disease-landscape-forecast-g7-2019","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0015-2019-biopharma-gastroesophageal-cancer-disease-landscape-forecast-g7-2019\/","title":{"rendered":"Gastroesophageal Cancer | Disease Landscape &#038; Forecast | G7 | 2019"},"content":{"rendered":"<p>The incidence of <gwmw class=\"ginger-module-highlighter-mistake-type-1\" id=\"gwmw-15854614452518675463977\">gastroesophageal<\/gwmw> cancer\u2014encompassing gastric cancer, esophageal cancer, and gastroesophageal junction (GEJ) adenocarcinoma\u2014 continues to rise; however, treatment options remain limited. Targeted therapies, including Herceptin (Roche \/ Genentech \/ Chugai [for HER2-positive patients only]) and Cyramza (Eli Lilly), have been approved exclusively for gastric and GEJ adenocarcinoma patients across the major markets. Additional agents are also approved for later-line treatments in certain geographies, such as Keytruda (Merck &#038; Co.), Opdivo (Bristol-Myers Squibb), and Lonsurf (Taiho). A plethora of <gwmw class=\"ginger-module-highlighter-mistake-type-6\" id=\"gwmw-15854614497590276845711\">agents including<\/gwmw> immunotherapies, vaccines, and a variety of targeted therapies are vying for approval in <gwmw class=\"ginger-module-highlighter-mistake-type-1\" id=\"gwmw-15854614497597651877132\">underserved<\/gwmw> patient segments, such as <gwmw class=\"ginger-module-highlighter-mistake-type-1\" id=\"gwmw-15854614497590772837210\">resectable<\/gwmw> disease or the first-line metastatic setting.<\/p>\n<p><strong>Questions Answered<\/strong><\/p>\n<ul>\n<li>How do current treatment practices differ among esophageal, gastric, and GEJ cancer patients? Do these practices differ by geography, and which populations provide the greatest drug-treatment opportunities?<\/li>\n<li>What are interviewed experts\u2019 insights on the use of currently approved agents? What clinical needs remain unfulfilled, and on what opportunities can developers capitalize?<\/li>\n<li>Which drugs in late-phase development are poised to change the treatment landscape for <gwmw class=\"ginger-module-highlighter-mistake-type-1\" id=\"gwmw-15854614533626086759730\">gastroesophageal<\/gwmw> cancer? How are these agents being assessed, and how will they impact the <gwmw class=\"ginger-module-highlighter-mistake-type-1\" id=\"gwmw-15854614539916162560167\">gastroesophageal<\/gwmw> cancer market?<\/li>\n<li>What are the key market drivers and constraints in the <gwmw class=\"ginger-module-highlighter-mistake-type-1\" id=\"gwmw-15854614547630606474595\">gastroesophageal<\/gwmw> market, and how will the market evolve over the forecast period?<\/li>\n<\/ul>\n<p><strong>Content Highlights<\/strong><\/p>\n<p>Geographies: United States, EU5, Japan.<\/p>\n<p>Primary research: 20 country-specific interviews with thought-leading medical oncologists supported by survey data collected for this and other DRG research.<\/p>\n<p>Epidemiology: Diagnosed and recurrent incidence of <gwmw class=\"ginger-module-highlighter-mistake-type-1\" id=\"gwmw-15854614576514497350581\">gastroesophageal<\/gwmw> cancer by country, segmented by HER2 status, histology, stage I-IV, and line of therapy.<\/p>\n<p>Forecast: 10-year, <gwmw class=\"ginger-module-highlighter-mistake-type-1\" id=\"gwmw-15854614591828994429602\">annualized<\/gwmw>, drug-level sales and patient share of key <gwmw class=\"ginger-module-highlighter-mistake-type-1\" id=\"gwmw-15854614591823951146131\">gastroesophageal<\/gwmw> cancer therapies through 2028, segmented by brands \/ generics and market-relevant drug treatable populations.<\/p>\n<p>Emerging therapies: Phase III: 12 drugs; Phase I \/ II: ~30 drugs.<\/p>\n<p><strong>Product Description<\/strong><\/p>\n<p><em>Disease Landscape &#038; Forecast<\/em>\u00a0provides <gwmw class=\"ginger-module-highlighter-mistake-type-3\" id=\"gwmw-15854614615727683003316\">comprehensive market intelligence<\/gwmw> with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n","protected":false},"template":"","class_list":["post-390296","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-esophageal-cancer","biopharma-date-931"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390296","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390296\/revisions"}],"predecessor-version":[{"id":576554,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390296\/revisions\/576554"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390296"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}